What the FDA labels say about taking them together
Meclizine and scopolamine
Scopolamine's FDA label of June 10, 2025 names meclizine in its drug interactions section; the meclizine label PlainMeds reads does not name scopolamine. The scopolamine label: “Concomitant use of other drugs that cause central nervous system (CNS) adverse reactions or have anticholinergic properties may increase this effect.”
Check it at the source: the meclizine FDA label on DailyMed (effective June 2, 2025, Rising Pharma Holdings, Inc.); the scopolamine FDA label on DailyMed (effective June 10, 2025, Baxter Healthcare Corporation).
What does the meclizine label say about scopolamine?
Meclizine's label (effective June 2, 2025) does not name scopolamine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Meclizine Hydrochloride), Rising Pharma Holdings, Inc., effective June 2, 2025 (SPL set c9ddc39c-bc6b-42f1-8c5f-5aff2d79c4bd), via openFDA; the full label on DailyMed
What does the scopolamine label say about meclizine?
Scopolamine label, drug interactionsSystem (CNS) Adverse Reactions The concurrent use of TRANSDERM SCŌP with other drugs that cause CNS adverse reactions of drowsiness, dizziness or disorientation (e.g., sedatives, hypnotics, opiates, anxiolytics and alcohol) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may potentiate the effects of TRANSDERM SCŌP [see Warnings and Precautions ( 5.2 )].
Scopolamine label, warnings and precautionsConcomitant use of other drugs that cause central nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [see Drug Interactions ( 7.1 )].
Source: FDA drug label (Transderm Scop), Baxter Healthcare Corporation, effective June 10, 2025 (SPL set b877a694-a1d0-4280-937a-a06820b12a88), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Meclizine | Scopolamine | |
|---|---|---|
| Labeled for | Nausea and vomiting | Nausea and vomiting |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.0442 per tablet 12.5 mg tablet | $4.34 per patch 1 mg/3 day patch |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once